Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
作者信息
Al-Sawaf Othman, Zhang Can, Jin Hyun Yong, Robrecht Sandra, Choi Yoonha, Balasubramanian Sandhya, Kotak Alex, Chang Yi Meng, Fink Anna Maria, Tausch Eugen, Schneider Christof, Ritgen Matthias, Kreuzer Karl-Anton, Chyla Brenda, Paulson Joseph N, Pallasch Christian P, Frenzel Lukas P, Peifer Martin, Eichhorst Barbara, Stilgenbauer Stephan, Jiang Yanwen, Hallek Michael, Fischer Kirsten
机构信息
Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Cancer Institute, University College London, London, UK.
出版信息
Nat Commun. 2023 Oct 23;14(1):6724. doi: 10.1038/s41467-023-42562-2.
Abstract
摘要
相似文献
1
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.作者更正：慢性淋巴细胞白血病中维奈克拉联合奥妥珠单抗与苯丁酸氮芥联合奥妥珠单抗的随机CLL14研究的转录组图谱及5年结果。
Nat Commun. 2023 Oct 23;14(1):6724. doi: 10.1038/s41467-023-42562-2.
2
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.维奈托克联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（CLL14）：一项多中心、开放标签、随机、3 期临床试验的随访结果。
Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5.
3
Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View.维奈克拉联合奥妥珠单抗与苯丁酸氮芥联合奥妥珠单抗用于成人慢性淋巴细胞白血病一线治疗的成本效益：扩展的社会视角
Value Health. 2023 Apr;26(4):477-486. doi: 10.1016/j.jval.2022.11.002. Epub 2022 Nov 11.
4
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial. Venetoclax+Obinutuzumab 在慢性淋巴细胞白血病中的药代动力学和暴露-反应分析：1b 期研究和 3 期 CLL14 试验。
Adv Ther. 2022 Aug;39(8):3635-3653. doi: 10.1007/s12325-022-02170-w. Epub 2022 Jun 16.
5
6
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.加拿大维奈托克和奥妥珠单抗作为慢性淋巴细胞白血病一线治疗方案的概率成本效益分析
Pharmacoecon Open. 2023 Mar;7(2):199-216. doi: 10.1007/s41669-022-00375-x. Epub 2022 Nov 5.
7
The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?伴有合并症的慢性淋巴细胞白血病患者使用奥滨尤妥珠单抗联合苯丁酸氮芥方案的疗效减退——我们是否已经准备好采用无化疗免疫治疗方法？
Expert Rev Hematol. 2020 Jul;13(7):771-779. doi: 10.1080/17474086.2020.1775575. Epub 2020 Jun 24.
8
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.伊布替尼联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病（ILLUMINATE）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.
9
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.维奈托克联合奥滨尤妥珠单抗治疗伴有合并症的 CLL 患者
N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.
10
Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia.维奈托克：初治慢性淋巴细胞白血病的治疗药物。
Drugs. 2020 Dec;80(18):1973-1980. doi: 10.1007/s40265-020-01433-6.
引用本文的文献
1
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment.慢性淋巴细胞白血病分子生物学的最新进展：如何定义预后并指导治疗
Cancers (Basel). 2024 Oct 14;16(20):3483. doi: 10.3390/cancers16203483.
2
Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review.慢性淋巴细胞白血病的创新联合疗法、细胞疗法和双特异性抗体：一项叙述性综述
Cancers (Basel). 2024 Mar 26;16(7):1290. doi: 10.3390/cancers16071290.
Zotero 插件